| scholarly article | Q13442814 |
| P2093 | author name string | Richard S Finn | |
| Saeed Sadeghi | |||
| P2860 | cites work | Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma | Q28293076 |
| Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas | Q33338191 | ||
| Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study | Q33362191 | ||
| Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study | Q33364964 | ||
| Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial | Q33365628 | ||
| Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. | Q33392786 | ||
| Prospective phase II trial of gemcitabine in combination with irinotecan as first-line chemotherapy in patients with advanced biliary tract cancer | Q33395417 | ||
| Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas | Q33914989 | ||
| Phase II study of erlotinib in patients with advanced biliary cancer | Q33997258 | ||
| Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors | Q34104493 | ||
| Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer | Q34618537 | ||
| Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. | Q34637757 | ||
| Pathogenesis, diagnosis, and management of cholangiocarcinoma | Q34656747 | ||
| Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers | Q35023456 | ||
| Risk factors for cholangiocarcinoma | Q35074664 | ||
| Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial | Q36614800 | ||
| A Multicenter Phase II Trial with Irinotecan plus Oxaliplatin as First-Line Treatment for Inoperable/Metastatic Cancer of the Biliary Tract | Q42924535 | ||
| Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study | Q43237133 | ||
| A phase II trial of irinotecan (CPT-11) for unresectable biliary tree carcinoma. | Q43634488 | ||
| First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract. A multicentre phase II study | Q43750756 | ||
| A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer | Q46147119 | ||
| Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. | Q53393758 | ||
| P433 | issue | 4 | |
| P921 | main subject | cholangiocarcinoma | Q124292 |
| systemic therapy | Q1929812 | ||
| P304 | page(s) | 86-89 | |
| P577 | publication date | 2014-04-28 | |
| P1433 | published in | Clinical liver disease | Q27726171 |
| P1476 | title | Systemic therapy for cholangiocarcinoma | |
| P478 | volume | 3 |
Search more.